Mutagenesis as a novel target for cancer prevention

诱变作为癌症预防的新靶点

• 批准号: 7031572
• 负责人: WILLIAM G MCGREGOR
• 金额: $ 21.58万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-01 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7031572
• 关键词: DNA directed DNA polymerase; biotechnology; cancer prevention; chemoprevention; disease /disorder model; enzyme activity; gene delivery system; gene therapy; genetic promoter element; genetically modified animals; laboratory mouse; lipids; mutagens; neoplasm /cancer genetics; nonhuman therapy evaluation; plasmids; radiation carcinogenesis; reporter genes; ribozymes; skin neoplasms; therapy design /development; tissue /cell culture; transfection /expression vector; ultraviolet radiation

DESCRIPTION (provided by applicant): The overall aim of this project is to apply new knowledge of fundamental mechanisms of mutagenesis to directly test the somatic mutation hypothesis of cancer, and to translate this knowledge into a clinically useful regimen to reduce the incidence of sunlight-associated skin cancer. Mutations in DNA are generally considered to have an etiologic role in the development of cancer, but until recently it has not been possible to directly examine the relative contribution of mutagenesis and epigenetic alterations in cellular physiology induced by carcinogen exposure. We hypothesize that mutations induced by ultraviolet light (UV) in the DNA of actively dividing skin cells are causally involved in skin carcinogenesis, and reducing the frequency of such mutations will reduce the risk of skin cancer induced by UV. There is now abundant evidence that virtually all mutations induced by UV in eukaryotic cells are dependent on the gene products encoded by the REV1 and REV3 genes. We showed further that targeting the mRNA of one of these genes (REV1) with gene-specific ribozymes virtually abolishes UV mutagenesis. To test our hypothesis, we propose to expose newly-developed REV3-depleted transgenic mice to UV. We anticipate that these mice will have a greatly reduced risk of developing skin cancer compared with control animals. Further, we propose to translate our data into a practical method to prevent UV-induced skin cancer. We will develop and optimize gene-specific ribozymes expressed in cultured cells using several different systems to target them to the cytoplasm or to the nucleus. Then, we propose to deliver such ribozyme expression vectors into mouse skin cells. These ribozymes will specifically target REV1 mRNA, a protein that may coordinate the activity of several proteins that are required for the mutagenic replication of UVdamaged DNA. The mice and the appropriate controls will be exposed to UV protocols that are known to induce skin cancer. Our hypothesis predicts that reducing the level of this protein will reduce the mutagenic response of skin cells to UV, and will result in a greatly reduced incidence of skin cancer. If so, these data will provide the experimental rationale to develop similar strategies to reduce the incidence of skin cancer in humans. Most importantly, such a strategy should be successful as a preventive measure after UV exposure and prior to appearance of disease symptoms.

描述（由申请人提供）：该项目的总体目标是应用突变基本机制的新知识来直接测试癌症的体细胞突变假说，并将这些知识转化为临床上有用的治疗方案，以降低与阳光相关的皮肤癌的发病率。 DNA突变通常被认为在癌症的发展中具有病因学作用，但直到最近，还不可能直接检查致癌物暴露引起的细胞生理学突变和表观遗传改变的相对贡献。我们假设，活跃分裂的皮肤细胞的 DNA 中由紫外线 (UV) 引起的突变与皮肤癌的发生有关，减少此类突变的频率将降低紫外线诱发皮肤癌的风险。现在有大量证据表明，几乎所有由紫外线在真核细胞中诱导的突变都依赖于 REV1 和 REV3 基因编码的基因产物。我们进一步表明，用基因特异性核酶靶向这些基因之一（REV1）的 mRNA 实际上消除了紫外线诱变。为了检验我们的假设，我们建议将新开发的 REV3 耗尽的转基因小鼠暴露在紫外线下。我们预计，与对照动物相比，这些小鼠患皮肤癌的风险将大大降低。此外，我们建议将我们的数据转化为预防紫外线诱发的皮肤癌的实用方法。我们将使用几种不同的系统开发和优化在培养细胞中表达的基因特异性核酶，将其靶向细胞质或细胞核。然后，我们建议将这种核酶表达载体递送到小鼠皮肤细胞中。这些核酶将专门针对 REV1 mRNA，这是一种可以协调紫外线损伤 DNA 诱变复制所需的几种蛋白质活性的蛋白质。小鼠和适当的对照将暴露于已知会诱发皮肤癌的紫外线方案。我们的假设预测，降低这种蛋白质的水平将减少皮肤细胞对紫外线的诱变反应，从而大大降低皮肤癌的发病率。如果是这样，这些数据将为开发类似策略来降低人类皮肤癌的发病率提供实验依据。最重要的是，这种策略作为紫外线照射后和疾病症状出现之前的预防措施应该是成功的。